Skip to content

Study on the New Technology Application and Mechanism of Temporal Interference Stimulation in the Treatment of Auditory Hallucinations in Schizophrenia

Study on the New Technology Application and Mechanism of Temporal Interference Stimulation in the Treatment of Auditory Hallucinations in Schizophrenia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126171
Enrollment
Unknown
Registered
2026-06-04
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with persistent auditory hallucinations (total score of the Auditory Hallucination Rating Scale (AHRS) > 18).

Interventions

TPJ-tTIS intervention group (A group):Transcranial time-interference stimulation (tTIS) targeting the temporoparietal junction (TPJ), for 10 sessions
vHPC-tTIS intervention group (B group):Transcranial time-interference stimulation (tTIS) targeting the ventral hippocampus (vHPC), for 10 sessions
Sham stimulation intervention group (C group):Sham stimulation intervention, for 10 sessions

Sponsors

Suzhou Guangji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for schizophrenia according to DSM-5; 2. Aged 18–55 years; 3. Have persistent auditory hallucinations (total score of the Auditory Hallucination Rating Scale (AHRS) > 18); 4. Right-handed, with normal hearing, vision or corrected vision; 5. Written informed consent obtained from patients and their families.

Exclusion criteria

Exclusion criteria: 1. Patients with organic brain diseases, psychoactive substance or alcohol dependence, epilepsy, or intellectual disability were excluded; 2. Patients with severe or unstable physical diseases, or clinically significant abnormal laboratory results judged by the researchers to affect subject safety were excluded; 3. Patients with contraindications to tTIS: intracranial metallic foreign bodies, cochlear implants, or intracranial hypertension; 4. Patients who had received ECT within 6 months; 5. Pregnant or lactating women, and women of childbearing age with a positive urine HCG test during the screening period; 6. Patients with obvious negative, impulsive, or disorganized behaviors who cannot cooperate with the examination; 7. Other conditions considered unsuitable for participation in this clinical trial by the researchers.

Design outcomes

Primary

MeasureTime frame
Auditory Hallucination Rating Scale (AHRS);

Secondary

MeasureTime frame
Positive and Negative Symptom Scale (PANSS);Clinical General Impression Scale (CGI);Functional magnetic resonance detection;Electroencephalogram detection;Calgary Schizophrenia and Depression Scale (CDSS);Simpson-Angus Scale (SAS);

Countries

China

Contacts

Public ContactGan Hong

Suzhou Guangji Hospital

15502117505@163.com+86 512 64797704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026